Scientists from USC Marshall conducted a study to see what kind of effect a gadget’s color had on its long-term likability. And the results? In short, don’t be scared; skip the black and silver and go with the hue or shade that really speaks to you.
In their experiment, Eva C. Buechel and Claudia Townsend separated products into two categories: high-arousal devices (like those with intense colors or complex patterns) and low-arousal products designed with less stimulating colors like beige, black, or silver. From there, they performed a series of tests that involved asking participants to evaluate each product on things like predicted likability or irritation, and then again after participants had gotten a chance to actually use each product over varying periods of time.
Read the full article: Stop Waffling and Get That Brightly Colored Gadget—Science Suggests You’ll Like It More (Gizmodo)
CompoSecure, L.L.C., a pioneer and global leader in the design and manufacturing of premium financial cards, today announced that it has produced more than one million dual interface (EMV chip & contactless) metal cards. Style and innovation have come together to make these “must have” cards in the discerning consumer’s wallet. The global adoption of contactless payment cards is demonstrated in a new study by A. T. Kearney, which also points to future growth for this technology, especially in the U.S.
“This milestone secures CompoSecure’s leadership position as the number one producer of premium payment cards,” said Jon Wilk, CEO of CompoSecure. “Integrating the contactless technology into these next generation metal cards is extremely challenging. Only CompoSecure has cracked the code on supporting financial institution clients in their large-scale program launches that include metal cards. The global push for contactless cards by all of the major payment brands made this more important than ever.”
Read the full release: CompoSecure Manufactures One Million Dual Interface Premium Cards (BusinessWire)
The FM/a Test, a clinical diagnostic blood test which is performed by Los Angeles-based EpicGenetics, has been approved for use by the U.S. Food and Drug Administration (FDA). And now, EpicGenetics and Massachusetts General Hospital (MGH) are launching a Phase II clinical trial to test a tuberculosis vaccine, BCG, as a potential treatment for fibromyalgia.
The structure of the clinical trial is to enroll 300 patients who test positive for fibromyalgia with the FM/a Test. They will be split into two groups, one receiving the vaccine, the other receiving a placebo.
“Currently,” says Bruce Gillis, CEO of EpicGenetics, “the only objective way to get fibromyalgia confirmed is by having the test. We’re in the process of contacting the people who had the test and seeing if they want to participate. We’re encouraging other people who want to potentially volunteer to also get the test, so we can do this. The expectation is that if the results are as good as we hope, potentially in as little as six months, we will have further opportunity to expand the treatment to many, many more people as we collect the data. We don’t expect significant side effects and we expect fairly rapid responses to the BCG by the people who participate in the trial who receive it.”
Read the full article: EpicGenetics and Massachusetts General Hospital to Launch Fibromyalgia Clinical Trial (BioSpace)
CURE Pharmaceutical has signed a deal with Canopy Growth Corp (TSX:WEED, NYSE:CGC), where Canopy will have an exclusive license to CURE’s patented, multi-layer oral thin film technology for use with cannabis extracts and biosynthetic cannabinoids.
Jessica Rousset, COO for CURE Pharmaceutical, says the licence agreement allows CURE to accelerate and expand the impact of its technology by joining forces with Canopy, which has broad market access and resources to bring a product to market.
See coverage below:
CURE Pharmaceutical joins forces with Canopy Growth in exclusive partnership (Proactive Investors)
CURE Pharmaceutical Expands Distribution of CUREfilm Technology With First Licensing Agreement (Drug Development and Delivery)
Canopy Growth Corp. Scores Huge Pharma Deal (Motley Fool)
Private lending syndication platform CrowdOut Capital announced on Wednesday the completion of a multi-million dollar term loan to Shale Support, a provider of frac sand and logistical solutions to the oil and gas proppant market.
According to CrowdOut, the loan will support the acquisition of two sand mines, spanning over 1,000 acres that contain more than 100 million tons of recoverable high-grade frac sand, which are located near the prolific shale plays in the southeastern U.S., and finance capital expenditures to increase production capacity at the sand mines.
Read the full article: CrowdOut Provides Multi-Million Dollar Term Loan to Shale Support (CrowdFund Insider)
TaskUs, the leader in next-generation customer experience outsourcing based in Santa Monica, Calif., has announced it will bring at least 700 new jobs over the next five years to Albuquerque.
TaskUs will invest $9 million in its new Technical Operations and Customer Experience Center at 200 Third Street in downtown Albuquerque. New Mexico beat Utah, Nevada and Texas for latest expansion.
“New Mexico was just a common sense next location. It’s closer to the west coast where our customers are, you’ve got direct flights from Los Angeles and San Francisco and both the state of New Mexico and the city of Albuquerque have worked really hard to get our business,” said Bryce Maddock, CEO of TaskUs.
See video and additional coverage below:
Tech firm will bring nearly 700 jobs to the Duke City (KOAT)
Tech company brings nearly 700 jobs to Albuquerque (KRQE)
California company plans 700 jobs for Downtown ABQ (Albuquerque Business First)
“Work hard, play hard.” According to TaskUs CEO and President Jaspar Weir, it’s time for this Sisyphean notion in the workplace to end. For years, startups have hinged their workplace cultures on creating this “balance,” yet time has shown that it fails more often than not. Burning the candle at both ends is not conducive for achieving optimal performance company-wide. On top of that, trying to maintain a rigorous workload and a highly active social life can be dangerous.
At TaskUs, “we think ‘work hard, have fun’ is a better way of putting it.”
Read the full article: Work Hard, Have Fun: Reclaiming A Combative Work Environment (Forbes)
Cloudbreak Health was just named among Becker’s Hospital Review’s 250+ telehealth companies to know for 2018.
Cloudbreak Health provides more than 1 million minutes of telemedicine consultation each month, linking patients and providers through the company’s telehealth marketplace. The company supports around 75,000 encounters per month at more than 700 hospitals, addressing telepsychiatry, telestroke, tele-ICU and telesitting functions.
The telehealth companies featured on this list range from video conferencing and connection to wearable data gathering and reporting technologies and platforms.
See the full list: 250+ telehealth companies to know | 2018 (Becker’s Hospital Review)
It’s back-to-school time and with the help of First Student, riders and parents can be certain they’re safe on their way to school. This morning, First Student showcased school bus safety tips for students and parents.
As the leading school transportation solutions provider in North America, First Student moves more passengers per day than all U.S. airlines combined.
Read the full coverage:
School bus safety tips for students and parents (FOX 11)
Recomendaciones para garantizar la seguridad de los niños en autobuses escolares (Univision Los Angeles)
The Saban Community Clinic offered free vaccines for low income and uninsured families just in time for the start of school in the Los Angeles Unified School District.
The Saban Community Clinic hosted a daylong vaccination drive, located at 5205 Melrose Avenue.
Read the full coverage:
Free vaccinations offered Monday at Saban Community Clinic in Hollywood (FOX 11)
Hollywood Clinic Offers Free Vaccinations Ahead of LAUSD School Year (KTLA)
LA clinic offering free vaccinations for children, adults (ABC)